

Esteban SÃ¡ez-GonzÃ¡lez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6722411/publications.pdf>

Version: 2024-02-01

20
papers

293
citations

933447

10
h-index

940533

16
g-index

20
all docs

20
docs citations

20
times ranked

422
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma Oncostatin M, TNF- α , IL-7, and IL-13 Network Predicts Crohn's Disease Response to Infliximab, as Assessed by Calprotectin Log Drop. <i>Digestive Diseases</i> , 2021, 39, 1-9.	1.9	8
2	Oxidative Stress in the Pathogenesis of Crohn's Disease and the Interconnection with Immunological Response, Microbiota, External Environmental Factors, and Epigenetics. <i>Antioxidants</i> , 2021, 10, 64.	5.1	41
3	Sucrosomial Iron Supplementation for the Treatment of Iron Deficiency Anemia in Inflammatory Bowel Disease Patients Refractory to Oral Iron Treatment. <i>Nutrients</i> , 2021, 13, 1770.	4.1	6
4	Specific Plasma MicroRNA Signatures in Predicting and Confirming Crohn's Disease Recurrence: Role and Pathogenic Implications. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00416.	2.5	7
5	Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease. <i>Digestive Diseases</i> , 2019, 37, 108-115.	1.9	32
6	The combination of granulocyte-monocyte apheresis and vedolizumab: A new treatment option for ulcerative colitis?. <i>Journal of Clinical Apheresis</i> , 2019, 34, 680-685.	1.3	14
7	Epigenetics of Inflammatory Bowel Disease: Unraveling Pathogenic Events. <i>Crohn's & Colitis 360</i> , 2019, 1, .	1.1	5
8	Bases for the Adequate Development of Nutritional Recommendations for Patients with Inflammatory Bowel Disease. <i>Nutrients</i> , 2019, 11, 1062.	4.1	8
9	Influence of Vitamin D Deficiency on Inflammatory Markers and Clinical Disease Activity in IBD Patients. <i>Nutrients</i> , 2019, 11, 1059.	4.1	30
10	A Nomogram Combining Fecal Calprotectin Levels and Plasma Cytokine Profiles for Individual Prediction of Postoperative Crohn's Disease Recurrence. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1681-1691.	1.9	28
11	Identification of Epigenetic Methylation Signatures With Clinical Value in Crohn's Disease. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00083.	2.5	22
12	Different Genetic Expression Profiles of Oxidative Stress and Apoptosis-Related Genes in Crohn's Disease. <i>Digestion</i> , 2019, 100, 27-36.	2.3	3
13	A concise review of opioid-induced esophageal dysfunction: is this a new clinical entity?. <i>Ecological Management and Restoration</i> , 2018, 31, .	0.4	24
14	Combination therapy with cytapheresis plus vedolizumab in a corticosteroid-dependent patient with ulcerative colitis and previous ANTI-TNF- α drug failure. <i>Digestive and Liver Disease</i> , 2018, 50, 415-417.	0.9	6
15	Adsorptive granulocyte/monocyte apheresis use in severe ulcerative colitis and determination of changes in plasma cytokines. <i>Journal of Clinical Apheresis</i> , 2018, 33, 99-103.	1.3	2
16	Impact of hepatitis C virus (<sc>HCV</sc>) antiviral treatment on the need for liver transplantation (<sc>LT</sc>). <i>Liver International</i> , 2018, 38, 1022-1027.	3.9	20
17	Immunological Mechanisms of Adsorptive Cytapheresis in Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1417-1425.	2.3	12
18	Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1454-1460.	1.9	25

#	ARTICLE	IF	CITATIONS
19	Opioid-induced functional esophagogastric junction obstruction. <i>Gastroenterology</i> y <i>Hepatology</i> (English Edition), 2017, 40, 296-298.	0.1	0
20	Tu1948 Î±-Defensins (Î±Def) 1-3 Are Specific Plasmatic Markers for Crohn's Disease (CD) at Diagnosis and Tissue Î±-Def 5 Methylation Is a Pathogenic Mechanism for Î±Def-5 Down Regulation in CD. <i>Gastroenterology</i> , 2016, 150, S987.	1.3	0